A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL

Trial Profile

A Phase I/II Open-label Study of Clofarabine in Patients With Relapsed or Refractory Diffuse Large Cell B-Cell NHL

Completed
Phase of Trial: Phase I/II

Latest Information Update: 29 Apr 2015

At a glance

  • Drugs Clofarabine (Primary)
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 06 Jul 2012 Actual patient number changed from 36 to 33 as reported by ClinicalTrials.gov.
    • 06 Jul 2012 Actual patient number changed from 36 to 33 as reported by ClinicalTrials.gov.
    • 28 Jul 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top